Mycobacterium tuberculosis Complex Detection and Rifampin Resistance (PCR), Acid-fast Bacillus (AFB) Smear, and AFB Culture with Reflex to Identification and Susceptibility Testing (Nonsputum)
CPT:
87116; 87206; 87556; 87798
Special Instructions
Specimen processing (i.e., N-acetyl-L-cystine-sodium hydroxide treatment or equivalent, concentration, grinding, both or neither), mycobacterial culture and smear when appropriate (smears are not performed on blood or when there is less than 2 mL of fluid). Identification by real-time polymerase chain reaction (PCR), and/or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, and/or nucleic acid sequencing, will be performed at an additional charge. This culture will often detect Nocardia species and other aerobic actinomyces, and identification appropriate for these organisms will be included.
Expected Turnaround Time
48 - 56 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Bronchial washings or bronchoalveolar lavage (BAL) specimens, pleural fluid or cerebrospinal fluid (CSF)
Volume
5 mL
Minimum Volume
5 mL (Note: This volume does not allow for repeat testing.)
Container
Sterile container with screw-cap seal
Storage Instructions
Refrigerate. If sample is to be split for other tests, specimen should be divided at the time of collection so that each portion is transported at the appropriate temperature.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | Culture: 3 days NAA: 7 days |
|
||||||
|
Test Details
Use
This test is used to detect and identify Mycobacterium tuberculosis complex and an rpoB mutation that is associated with rifampin resistance.
Limitations
This assay should not be used to test specimens from patients that have been treated with antituberculous drugs for more than three days. This assay should not be used to monitor therapy or as a test of cure. A negative test does not exclude the possibility of isolating M. tuberculosis complex isolates from culture. Assay interference may occur in the presence of lidocaine, mucin, ethambutol, guaifenesin, phenylephrine and tea tree oil. Lower sensitivity may be observed in pediatric patients due to the diffuse nature of M. tuberculosis infection in the lungs of this patient group and difficulties encountered in obtaining adequate specimens.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
Nucleic acid amplification (NAA), nested real-time polymerase chain reaction (PCR); concentrated specimen with broth-based and/or agar-based culture. Culture is held for six weeks before negative is reported. Organisms from culture are identified by use of real-time polymerase chain reaction (PCR) and/or MALDI-TOF and/or nucleic acid sequencing.
LOINC® Map
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf